

# The Cochrane Library

碩睿資訊

Shou Ray Information Service

2020

Trusted evidence.  
Informed decisions.

Better health.



# 大綱



**Cochrane**



# 資料庫簡介

# 為什麼需要 The Cochrane Library?

## 持續知識 需求

「你們現在在醫學院所學到的，其中有一半在十年內將會被證實是錯誤的；糟糕的是，連你的老師也不知道哪些是錯誤的。」

~Dr. Sydney Burwell  
(1956 Dean, Harvard Medical School)

## 時間有限

>2百萬篇文章發表於2萬種生物醫學期刊/年  
→台北101大樓(500公尺)  
>**21篇**/天→掌握核心發展最新狀況

## 專業審閱 專業推薦


醫學界重要的出版品一致推崇Cochrane Review是目前**最具參考價值的系統評論(Gold Standard)**

THE  
LANCET



JAMA<sup>®</sup>  
The Journal of the American Medical Association


# 資料庫背景



Professor Archibald Leman Cochrane,  
CBE FRCP FFCM, (1909-1988)  
英國內科醫師及流行病學專家

- 使用已被證明有效果的醫療措施  
→ 避免醫療資源浪費
- 呼籲健康照護的成效應有實證研究支持  
→ RCT研究 **Randomized Controlled Trial**

1972



1992

**EBM Gordon**  
**Cochrane  
Collaboration  
@England**

**Cochrane Taiwan 成立  
@TMU**

2009

2015

**更名為  
The  
Cochrane**

**目標：成  
為全球健  
康決策的  
證據核心**



# 實證醫學

evidence-based medicine


謹慎地、明確地、小心地採用

**目前最佳的證據**

作為照顧病人臨床決策的參考

Sackett, et al., 1996


# Evidence Pyramid



# 研究成果收錄成CDSR(Cochrane Database of Systematic Review) 一段時間會重新進行資料收集及評讀

7.755


2018 Journal Impact Factor



針對特定**臨床醫療照護問題**的介入方式評斷其療效  
協助醫療專業人士進行診療**判斷與決策**



# 收錄三個資料庫


收錄資料庫	特色
Cochrane Database of Systematic Reviews (Cochrane Reviews)	針對特定臨床問題(健康照護)的介入方式評斷其療效，是 <b>全文資料庫</b>
Cochrane Central Register of Controlled Trials (Clinical Trials)	收錄隨機臨床實驗的 <b>書目資料庫</b>
Clinical Answers (CCAs) <b>New</b>	從Cochrane Reviews擷取易讀、易懂的臨床切入重點，便於臨床照護的決策與操作
Other reviews	<div data-bbox="502 1078 561 1235" style="text-align: center;">↑</div> <div data-bbox="502 1251 774 1398" style="text-align: center;">               Epistemonikos         </div> <div data-bbox="789 1235 1093 1426" style="text-align: center;"> <b>New</b>              聯合檢索         </div> <div data-bbox="1566 1078 1625 1235" style="text-align: center;">↑</div>

# Cochrane Review的類型

Review 類型	說明
<b>Intervention reviews</b>	評估介入使用健康照護及健康策略的效益及傷害。
<b>Diagnostic test accuracy reviews</b>	評估在診斷和檢測特定疾病時的診斷測試執行表現。
<b>Methodology reviews</b>	解決系統性回顧和臨床試驗如何實施及被報告的相關議題。
<b>Qualitative reviews</b>	綜合質性的證據來解決有效以外的介入問題。
<b>Prognosis reviews</b>	解決可能發生的過程或健康有問題的人未來的狀況。

# Other Reviews

- 綜合最佳健康照護基礎證據、資訊科技和專家網絡為臨床決策或健康政策問題提供特別的工具。Cochrane使用者可連接Epistemonikos看到系統性回顧。




Cochrane Reviews 107 | Cochrane Protocols 15 | Trials 16329 | Editorials 2 | Special collections 0 | Clinical Answers 15 | **More** (dropdown)

**3207 Reviews matching for 'lung cancer in Title, Abstract'**

Note: The Cochrane Library search syntax (e.g. "AND"; "NEAR", etc) and field labels may not work in the same way in external databases.

Epistemonikos Systematic Reviews | Order by Relevancy | Results per page 25

- Lung cancer.**  
Frödin JE. Acta oncologica (Stockholm, Sweden). 1996;35 Suppl 7:46-53.
- Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium.**  
Brenner DR, Boffetta P, Duell EJ, Bickeböller H, Rosenberger A, McCormack V, Muscat JE, Yang P, Wichmann HE, Brueske-Hohlfeld I, Schwartz AG, Cote ML, Tjønneland A, Friis S, Le Marchand L, Zhang ZF, Morgenstern H, Szeszenia-Dabrowska N, ...



Epistemonikos | About | Help | Contact | Sign up

Search in any of the 9 supported languages | Advanced search | Help

**Lung cancer.**

Abstract

Authors: Frödin JE  
Category: Systematic review  
Journal: Acta oncologica (Stockholm, Sweden)  
Year: 1996  
Links: Pubmed

Resources  
Export Citation  
Create your own Matrix

Evidence related with this article: (not yet available)

Broad syntheses

# 資料庫介面

Sam Edwards/Getty Images



**Fluid resuscitation in critically ill people: colloids versus crystalloids**  
Read the review

Steve Debenport/Getty Images



**Prevention of acute malnutrition**  
Read the Special Collection

GARO/PHANIE/SciencePhotoLibrary



**Can Omega-3 prevent cardiovascular disease?**  
Read the review

Highlighted Reviews

Editorials

Special Collections

**Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term**

Alexandros Sotiriadis, George Makrydimas, Stefania Papatheodorou, John PA Ioannidis, Emma McGoldrick  
3 August 2018

**Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis**

Kevin W Southern, Sanjay Patel, Ian P Sinha, Sarah J Nevitt  
2 August 2018

**Antibiotics for prolonged wet cough in children**

Julie M Marchant, Helen L Petsky, Peter S Morris, Anne B Chang  
31 July 2018

4



Cochrane Interactive Learning  
Learn how to conduct Cochrane Reviews with Cochrane Interactive Learning

Browse by Topic

Browse by Cochrane Review Group

1

## Browse by Topic

Browse the *Cochrane Database of Systematic Reviews*

2

Allergy & intolerance

**b**

Blood disorders

**c**

Cancer

Child health

Complementary & alternative medicine

Consumer & communication strategies

**d**

Dentistry & oral health

Developmental, psychosocial & learning problems

Diagnosis

**e**

Ear, nose & throat

Effective practice & health systems

**g**

Gastroenterology & hepatology

Genetic disorders

Gynaecology

**h**

Health & safety at work

Health professional education

Heart & circulation

**i**

Infectious disease

**k**

Kidney disease

**l**

Lungs & airways

**m**

Mental health

Methodology

**n**

Neonatal care

Neurology

**o**

Orthopaedics & trauma

**p**

Pain & anaesthesia

Pregnancy & childbirth

Public health

**r**

Rheumatology

**s**

Skin disorders

**t**

Tobacco, drugs & alcohol

**u**

Urology

3



Podcasts

**Cochrane Podcasts: Listen to Cochrane evidence in under five minutes**

# Browse



## Browse by Topic

Browse the *Cochrane Database of Systematic Reviews*

選取有興趣的相關主題

- a**
  - Allergy & intolerance
- b**
  - Blood disorders
- c**
  - Cancer
  - Child health
  - Complementary & alternative medicine
  - Consumer & communication strategies
- d**
  - Dentistry & oral health
  - Developmental, psychosocial & learning problems
  - Diagnosis
- e**
  - Gastroenterology & hepatology
- f**
  - Genetic disorders
- g**
  - Gynaecology
- h**
  - Health & safety at work
  - Health professional education
  - Heart & circulation
- i**
  - Infectious disease
- k**
  - Kidney disease
- l**
  -
- n**
  - Neonatal care
  - Neurology
- o**
  - Orthopaedics & trauma
- p**
  - Pain & anaesthesia
  - Pregnancy & childbirth
  - Public health
- r**
  - Rheumatology
- s**
  - Skin disorders

[Highlighted Reviews](#) [Editorials](#) [Special Collections](#)

### Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term

Alexandros Sotiriadis, George Makrydimas, Stefania Papatheodorou, John PA Ioannidis, Emma McGoldrick

3 August 2018

### Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis


Kevin W Southern, Sanjay Patel, Ian P Sinha, Sarah J Nevitt

2 August 2018





**Filter your results**

**Date** 

Publication date


- The last 3 months ..... 14
- The last 6 months ..... 25
- The last 9 months ..... 45
- The last year ..... 66
- The last 2 years ..... 143

Custom Range:

to


[Apply](#) [Clear](#)

---

**Status** 

- New search ..... 127
- Conclusions changed ..... 28


---

**Language** 

- Español ..... 409


[Show 13 more](#) ▼


---

**Type** 

- Intervention ..... 662
- Diagnostic ..... 16
- Overview ..... 2

---

**Topics** 

- Cancer 
  - + Gynaecological ..... 100
  - + Palliative and supportive care ..... 92
  - + Haematological malignancies ..... 66
  - + Colorectal ..... 65
  - + Breast ..... 65
  - + General cancer treatments ..... 60

[Show 46 more](#) ▼

Trials 1290340 Editorials 120 Special collections 24 Clinical Answers 1738 [More](#) ▼

h All Text'

[Show all previews](#)

Results per page

**and radiation therapy for treating locally advanced cervix**

on Pijls-Johannesma, Danielle FM De Haas-Kock, Jeroen Buijsen, Ghislaine APG De Ruyscher, Philippe Lambin

17 March 2010

---

**llowed by lymph node dissection for localised primary**

s, Simone Mocellin, Zoe Apalla, Aimilios Lallas, Pierluigi Pilati, Alexander Stratigos

16 May 2015  Free access

選取相關主題的子分類

# 瀏覽方式

Filter your results

Date i

Publication date

The last 3 months ..... 1

The last 6 months ..... 1

The last 9 months ..... 3

The last year ..... 3

The last 2 years ..... 6

Custom Range:

to

Status i

New search x

Conclusions changed ..... 6

Language i

簡體中文 ..... 3

Show 11 more ▾

Type i

Intervention ..... 20

Topics i

Allergy & intolerance x

+ Allergic asthma ..... 7

Topics: Allergy & intolerance ✕ Status: New search ✕

20 Cochrane Reviews matching **Allergy & intolerance** in Cochrane Topic

- ◆ 瀏覽是藉由各種條件以限縮資料的流程
- ◆ 在左方限縮條件點選一個選項就會在上方出現一個過濾器，可點按 x 自行移除

## Browse by Cochrane Review Group

Browse the *Cochrane Data*

**a**

Acute Respiratory Infection

Airways

Anaesthesia, Critical, and Emergency  
Care

**b**

Back and Neck

選取相關的  
評論小組

Childhood Cancer

Colorectal Cancer

Common Mental Disorders

Consumers and Public Involvement

Cystic Fibrosis and Genetic

**d**

Dementia and Cognitive Improvement

Developmental, Psychosocial and Learning Problems

Drugs and Alcohol

Type

Intervention ..... 351

Overview ..... 3

Diagnostic ..... 1

Topics

+ Lungs & airways ..... 351

+ Child health ..... 197

+ Complementary & alternative medicine ..... 20

+ Allergy & intolerance ..... 14

+ Neurology ..... 11

+ Infectious disease ..... 6

+ Pain & anaesthesia ..... 3

Show 6 more ▾

選取相關主題的子分類，  
並閱讀全文

Inflammatory Bowel Disease

Injuries

**k**

Kidney and Transplant

**l**

exacerbations of chronic obstructive pulmonary disease

Douglas C McCrory, Cynthia D Brown

Show Preview ▾ Intervention Review 20 January 2003

5

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease

Jimmy Chong, Charlotta Karner, Phillippa Poole

Show Preview ▾ Intervention Review 12 September 2012

6

Aclidinium bromide for stable chronic obstructive pulmonary disease

Han Ni, Zay Soe, Soe Moe

Show Preview ▾ Intervention Review 19 September 2014 Free access

7

Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease

Sarah Appleton, Terry Jones, Phillippa Poole, Toby J Lasserson, Robert Adams, Brian Smith, Julia Muhammed

Show Preview ▾ Intervention Review 19 July 2006 New search

Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease

Peter C Gøtzsche, Helle Krogh Johansen

Show Preview ▾ Intervention Review 20 September 2016 New search Free access

**l**

Tobacco Addiction

**u**

Upper GI and Pancreatic Diseases

Urology

**v**

Cochrane Database of Systematic Reviews

## Colloids versus crystalloids for fluid resuscitation in critically ill people

Cochrane Systematic Review - Intervention | Version published: 03 August 2018 [see what's new](#)

<https://doi.org/10.1002/14651858.CD000567.pub7>

New search [Conclusions changed](#)  37 [View article information](#)

[✉ Sharon R Lewis](#) | [Michael W Pritchard](#) | [David JW Evans](#) | [Andrew R Butler](#) | [Phil Alderson](#) | [Andrew F Smith](#) | [Ian Roberts](#)

[View authors' declarations of interest](#)

[Collapse all](#) [Expand all](#)

### Abstract

Available in [English](#) | [Español](#) | [Français](#) | [Português](#) | [简体中文](#)

### Background

Critically ill people may lose fluid because of serious conditions, infections (e.g. sepsis), trauma, or burns, and need additional fluids urgently to prevent dehydration or kidney failure. Colloid or crystalloid solutions may be used for this purpose. Crystalloids have small molecules, are cheap, easy to use, and provide immediate fluid resuscitation, but may increase oedema. Colloids have larger molecules, cost more, and may provide swifter volume expansion in the intravascular space, but may induce allergic reactions, blood clotting disorders, and kidney failure. This is an update of a Cochrane Review last published in 2013.

### Objectives





To assess the effect of using colloids versus crystalloids in critically ill people requiring fluid volume replacement on mortality, need for blood transfusion or renal replacement therapy (RRT), and adverse events (specifically: allergic reactions, itching, rashes).

### Search methods

We searched CENTRAL, MEDLINE, Embase and two other databases on 23 February 2018. We also searched clinical trials registers.

### Selection criteria

We included randomised controlled trials (RCTs) and quasi-RCTs of critically ill people who required fluid volume replacement in

-  [View PDF](#) ▾
-  [Cite this Review](#)
-  [Request Permissions](#)
-  [Comment on Review](#)
- Read comments on this Review(0)

-  [Print](#)
-  [Share](#)
-  [Follow](#)

[Linked to this Review \(5\)](#) ▾

#### Abstract




- [Plain language summary](#)
- [Authors' conclusions](#)
- [Summary of findings](#)
- [Background](#)
- [Objectives](#)
- [Methods](#)
- [Results](#)
- [Discussion](#)

#### Appendices

- [Information](#)
- [Authors](#)
- [History](#)
- [Keywords](#)



#### Translation notes

- [References](#)
- [Characteristics of studies](#)
- [Data and analyses](#)

-  [Figures and tables](#)
-  [Download statistical data](#)
-  [Related content](#) Podcast available

# 註冊帳號

1. 點選首頁的Sign in  
2. 出現新視窗後，點選Register  
註冊 Cochrane library 帳號



單位權限IP範圍內註冊即可利用下述功能：  
提供My Profile的功能  
儲存檢索條件  
Alert功能

### 3. 進入到Wiley Online Library平台的註冊畫面。填入個人E-mail、密碼、個人姓名、國家地區等資訊，並且勾選Term of Use後，Submit Registration。

請將有  
星號\*的欄位  
正確填寫後提交

Register as a new user

**Login information**

Email or Customer ID\*  Password\*

Retype email\*  Confirm password\*

A one-time confirmation email will be sent to this address. Your email address will serve as your login name. Must be at least 10 characters long, and contain at least three of following: Lowercase letter (a-z) | Uppercase letter (A-Z) | Number (0-9) | Special Character

**Personal profile**

First Name\*  Country/Location\*

Last Name\*  Area of interest\*

First name and last name should be alphanumeric with the following allowed characters: hyphen(-), single quote('), space and dot.

**Sign up for Email lists**

Yes, I consent to receive marketing email on Wiley products and services and have read Wiley's Privacy Policy

No, thank you... I do not wish to receive email from Wiley

Note that you may still receive transactional messages though unsubscribed from commercial email.

**Sign up for print mail lists**

Please include me on your mailing list to receive brochures and other printed information about books and journals in my areas of interest.

Organization  Department

Address line 1\*  Address line 2

送出後請回註冊  
信箱收取確認信

## 4. 輸入剛剛註冊的Email以及密碼， 點選頁面的Sign In登入 Cochrane library 帳號

Sign In ✕

Email Address

Password

Remember Me?

[Forgotten password?](#)

Sign In

Register [↗](#)

Institutional Login

English

Cochra

4

[Sign In](#)

Title Abstract Keyword




Browse

Advanced search



# 帳號

- ◆ 因應平台轉換，登入舊帳號需依照新條件重新設定密碼，請記得到Email裡面收信點按 [return to Wiley Online Library](#) 去重設密碼



# 實證醫學檢索

## 5As

### Standard EBM Steps in EBM process

Ask

Formulate an answerable question  
**PICO**

Acquire

Track down the best evidence

Appraisal

Critically appraise the evidence

Apply

Integrate with clinical expertise and patient values

Audit

Critically appraise the evidence

P

Patient  
or  
Problem

病人或問題

I

Intervention  
or  
Indicator

介入或指標  
某種治療、檢查  
、危險因子等

C

Comparator  
or  
Comparison

比較  
該治療和什麼相比

O

Outcome

結果  
想達成或避免什  
麼結果

# 檢索

# 中文檢索

Title Abstract Keyword ▼

感冒

(Word variations have been searched)



Search limits

Send to search manager

Run search

Clear all

## Filter your results

Date



Publication date

The last 3 months ..... 0

The last 6 months ..... 0

The last 9 months ..... 1

The last year ..... 1

The last 2 years ..... 3

Cochrane Reviews  
15

Cochrane Protocols  
0

Trials  
0

Editorials  
0

Special collections  
0

Clinical Answers  
0

Other Reviews

15 Cochrane Reviews matching on '感冒' (Word variations have been searched)

15 results

Cochrane Database of Systematic Reviews

Issue 3 of 12, March 2019

Select all (15)    Export selected citation(s)    Show all previews

Order by Relevancy ▼

Results per page 25 ▼

- Chinese medicinal herbs for the common cold**  
Xiaoge Zhang, Taixiang Wu, Jing Zhang, Qiu Yan, Lingxia Xie, Guan J Liu  
[Show Preview](#)    Intervention    Review    24 January 2007

# 英文檢索

Title Abstract Keyword ▼ Common cold

(Word variations have been searched)




Search limits

Send to search manager

Run search

Clear all

## Filter your results

Date 

Publication date

The last 3 months ..... 2

The last 6 months ..... 4

The last 9 months ..... 5


The last year ..... 6

The last 2 years ..... 13

Custom Range:

 dd/mm/yyyy to  dd/mm/yyyy

Apply Clear

Status 

New search ..... 26

- Cochrane Reviews  
76
- Cochrane Protocols  
1
- Trials  
1661
- Editorials  
1
- Special collections  
0
- Clinical Answers  
2
- Other Reviews

**76 Cochrane Reviews matching on 'Common cold in Title Abstract Keyword - (Word variations have been searched)'**

76 results

Cochrane Database of Systematic Reviews  
Issue 9 of 12, September 2018

Select all (76) Export selected citation(s) Show all previews

Order by Relevancy ▼

Results per page 25 ▼

- Antihistamines for the common cold**  
An IM De Sutter, Marc Lemiengre, Harry Campbell  
[Show Preview](#) Intervention Review 7 October 2009 Withdrawn
- Antivirals for the common cold**  
Tom Jefferson, David Tyrrell  
[Show Preview](#) Intervention Review 23 July 2001 Withdrawn
- Corticosteroids for the common cold**  
Gail Hayward, Matthew J Thompson, Rafael Perera, Chris B Del Mar, Paul P Glasziou, Carl J Heneghan

# 進階檢索



# Advanced Search



Sam Edwards/Gettyimages

**Fluid resuscitation in critically ill people: colloids versus crystalloids**  
Read the review



SteveDebenport/Gettyimage

**Prevention of acute malnutrition**  
Read the Special Collection



GARO/PHANIE/SciencePhotoLibrary

**Can Omega-3 prevent cardiovascular disease?**  
Read the review



## Advanced Search

Please note that the Advanced Search is optimised for English search terms. Certain features, such as search operators and MeSH terms, are only available in English.

Search

Search manager

Medical terms (MeSH)


 Save search View searches Search help

自選檢索項 預設：Title, Abstract, Keywords

Title Abstract Keyword ▾




diabet

(Word variations have been added)

 Clear all...

- Diabetes Care Profile
- diabetes
- diabetes associated peptide
- diabetes control
- diabetes education research
- diabetes gravidarum
- diabetes insipidus
- diabetes mellitus

建議詞彙下拉選單

 Search limits Send to search manager Run search

## Advanced Search

### Search limits

#### Content type

- Cochrane Reviews
- Cochrane Protocols
- Trials
- Clinical Answers
- Editorials
- Special collections

#### Cochrane Library publication date

- All dates
- The last month
- The last 3 months
- The last 6 months
- The last 9 months
- The last year
- The last 2 years
- Between   and

#### CENTRAL Trials only

#### Original publication year

- All years
- Between  and

#### Search word variations

(e.g. "paid" will find pay, pays, paying, payed)

#### Cochrane Group

Choose Cochrane Group

檢索條件限制  
內容類型  
發布日期  
Cochrane Group

Clear

Apply limits

operators and MeSH terms, are only available in English.

Save search

View searches

Search help

Search limits

Send to search manager

Run search

# 檢索範例

多數住院患者在住院期間內，會接受透過靜脈導管注射輸液或藥物治療，通常例行每3至4天更換一次，以預防對靜脈的刺激或血液感染，但此例行程序可能造成患者的不適且相當昂貴，亦為醫療照護人員工作負擔與壓力的來源，因此醫院希望重新評估依臨床狀況移除周邊靜脈導管與常規移除並重新置入靜脈導管之局部感染和導管阻塞比率是否有顯著差異。

# 檢索範例

多數住院患者在住院期間內，會接受透過靜脈導管注射輸液或藥物治療，通常例行每3至4天更換一次，以預防對靜脈的刺激或血液感染，但此例行程序可能造成患者的不適及醫材消耗，亦為醫療照護人員工作負擔與壓力的來源，因此醫院希望重新評估依臨床狀況移除周邊靜脈導管與常規移除並重新置入靜脈導管之局部感染和導管阻塞比率是否有顯著差異。

# 檢索範例

**Participants  
Problems**

住院病人

**Interventions**

依臨床狀況更換周邊靜脈導管

**Comparisons**

常規更換周邊靜脈導管 (原來照護方式)

**Outcomes**

局部感染和導管阻塞比率

# 檢索範例

**Participants  
Problems**

**住院病人**  
In-patient

**Interventions**

**依臨床狀況更換周邊靜脈導管**  
Clinically-indicated replacement of peripheral venous catheters, Clinically-indicated IV replacement

**Comparisons**

**常規更換周邊靜脈導管** (原來照護方式)  
Routine replacement of peripheral intravenous catheters, routine IV replacement, routine removal of peripheral IV catheters

**Outcomes**

**局部感染和導管阻塞比率**  
Difference in peripheral catheter-related complications / phlebitis rates

(Word variations have been searched)


[Search limits](#)
[Send to search manager](#)
[Run search](#)

### Filter your results

#### Date i

##### Publication date

The last 3 months ..... 10

The last 6 months ..... 24

The last 9 months ..... 32

The last year ..... 41

The last 2 years ..... 66

##### Custom Range:

 to 

[Apply](#) [Clear](#)

#### Status i

New search ..... 84

Conclusions changed ..... 29

#### Language i

Español ..... 176

[Show 13 more](#) ▼

#### Type i

Intervention ..... 275

Cochrane Reviews  
293

Cochrane Protocols  
31

Trials  
76

Editorials  
0

Special collections  
1

Clinical Answers  
1

More  
▼

**293 Cochrane Reviews matching on 'routine IV replacement in All Text OR phiebits in All Text - (Word variations have been searched)'**

#### Cochrane Database of Systematic Reviews

Issue 8 of 12, August 2018

[Select all \(293\)](#)   [Export selected citation\(s\)](#)   [Show all previews](#)

Order by [Relevancy](#) ▼

Results per page [25](#) ▼

1  **Clinically-indicated replacement versus routine replacement of peripheral venous catheters**

Joan Webster, Sonya Osborne, Claire M Rickard, Karen New

[Show Preview](#) ▼   [Intervention](#)   [Review](#)   14 August 2015   [New search](#)   [Free access](#)

2  **Pharmacological interventions for the acute management of hyperkalaemia in adults**

Josh Batterink, Tara A Cessford, Robert Al Taylor

[Show Preview](#) ▼   [Intervention](#)   [Review](#)   27 October 2015   [Free access](#)

3  **Immunosuppressive treatment for proliferative lupus nephritis**

David J Tunnicliffe, Suetonia C Palmer, Lorna Henderson, Philip Masson, Jonathan C Craig, Allison Tong, Davinder Singh-Grewal, Robert S Flanc, Matthew A Roberts, Angela C Webster, Giovanni FM Strippoli

[Show Preview](#) ▼   [Intervention](#)   [Review](#)   29 June 2018   [New search](#)   [Conclusions changed](#)

4  **Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis**

Matthew N Hurley, Andrew P Prayle, Patrick Flume

[Show Preview](#) ▼   [Intervention](#)   [Review](#)   30 July 2015   [Free access](#)

5  **Blood biomarkers for the non-invasive diagnosis of endometriosis**



# Clinically-indicated replacement versus routine replacement of peripheral venous catheters

Cochrane Systematic Review - Intervention | Version published: 23 January 2019 [see what's new](#)

New search

[View article information](#)✉ [Joan Webster](#) | [Sonya Osborne](#) | [Claire M Rickard](#) | [Nicole Marsh](#)[View authors' declarations of interest](#)

## Abstract

### Background

US Centers for Disease Control guidelines recommend replacement of peripheral intravenous catheters (PIVC) no more frequently than every 72 to 96 hours. Routine replacement is thought to reduce the risk of phlebitis and bloodstream infection. Catheter insertion is an unpleasant experience for patients and replacement may be unnecessary if the catheter remains functional and there are no signs of inflammation or infection. Costs associated with routine replacement may be considerable. This is the third update of a review first published in 2010.

### Objectives

To assess the effects of removing peripheral intravenous catheters when clinically indicated compared with removing and re-siting the catheter routinely.

### Search methods

The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 18 April 2018. We also undertook reference checking, and contacted researchers and manufacturers to identify additional studies.

### Selection criteria

We included randomised controlled trials that compared routine removal of PIVC with removal only when clinically indicated, in hospitalised or community-dwelling patients receiving continuous or intermittent infusions.

 View PDF ▾ Cite this Review Request Permissions Comment on Review

Read comments on this Review(0)

 Print Share Email

#### Abstract

[Plain language summary](#)[Authors' conclusions](#)[Summary of findings](#)[Background](#)[Objectives](#)[Methods](#)[Results](#)[Discussion](#)[Appendices](#)[Information](#)[Authors](#)[History](#)[Keywords](#) [Translation notes](#)[References](#)[Characteristics of studies](#)[Data and analyses](#) [Figures and tables](#) [Download statistical data](#) [Related content](#)

## Replacing a peripheral venous catheter when clinically indicated versus routine replacement

### Review question

We reviewed the evidence about the effects of changing a peripheral venous catheter only if there were signs or symptoms of a problem with the catheter.

### Background

Most hospital patients receive fluids or medications through a peripheral venous catheter. An intravenous catheter (also called an IV drip, an IV line, or a peripheral IV) allow administration of medications, fluids or nutrients. Catheters are changed every three to four days to try to prevent irritation of the vein. Catheter change causes discomfort to patients and is quite costly. This is the reason for the review.

### Study characteristics

In April 2018 we searched for randomised controlled trials (RCTs) comparing (change) with changing the catheter only if there were signs or symptoms of blood stream infection, phlebitis and other problems such as catheter blockage. We included two new studies for this update.

### Key results

We found no clear difference in rates of catheter-related bloodstream infection from any cause, local infection, mortality, or pain when catheters are changed when clinically indicated. Infusion blockage (an inability to infuse fluids or medication) was reduced when catheters are replaced routinely. Cost is reduced when catheters are replaced only when clinically indicated. 'number of catheter re-sites per patient', and 'satisfaction with catheter care' were also assessed.

### Quality of the evidence

The overall quality of the evidence was judged to be low. The main reason for this uncertainty is largely due to outcomes, such as phlebitis, being assessed by people who were aware of the group allocation, which may or may not affect their decision about whether a problem is present or absent.

**淺顯易懂的口語結論** available in [English](#) | [Français](#) | [Polski](#) | [Русский](#) | [繁體中文](#)

### 依臨床狀況更換與常規更換周邊靜脈導管之比較

#### 回顧問題

我們回顧實證報告關於定期更換導管 (每 3至4天) 及只有在導管出現問題或症狀時才更換導管之差異。

#### 研究背景

大多數醫院患者在住院期間，通常會通過外周靜脈導管接受液體或藥物治療。靜脈導管 (也稱為靜脈滴注、靜脈或靜脈插管) 為放置在靜脈中的一個短且空心的管路，用於將藥物、液體或營養物質直接輸送到血液中。這些導管通常每三到四天更換一次，以防止靜脈刺激或血液感染。然而，更換導管可能會給患者帶來不適，而且成本相當高。本篇這是第三次更新首次發表於2010的評論文章。

#### 研究特點

2018年4月，我們尋找隨機對照試驗 (RCT)，僅在出現併發症或治療完成的情況下才更換導管及每72至96小時更換導管 (常規更換) 進行比較。我們測量導管相關的血液感染、靜脈炎和其他與外周導管有關的問題，如局部感染和導管堵塞。我們總共發現了9項研究，包含此次納入的兩項新研究，有7412名參與者。

#### 主要結果

我們發現，導管相關的血液感染率、靜脈炎 (靜脈炎症)、任何原因引起的血液流感染、局部感染、死亡率或疼痛的發生率並沒有顯著差異。依照臨床狀況更換導管，並無法確定局部感染是否因此減少或增加。常規更換導管者，滲漏 (液體滲入導管周圍的組織) 和導管堵塞 (無法通過導管注入液體或藥物) 可能會減少。在依照臨床徵兆才更換導管者，成本降低。研究結果的假設，「每名患者的導管重新置放管路次數」，及，「滿意度」並未包括在任何研究報告評價中。

#### 證據品質

證據整體的品質被批判對大多數結果是模稜兩可的，這研究的結果無法說服我們。不確定性主要歸因由於患者對靜脈炎等結果進行評估，這些結果可能或也可能不影響他們關於問題是否存在的決定。

# 情境

四十五歲男性，事業有成，父親過去因急性心肌梗塞猝死，因此一直注重養生不抽菸。定期接受健康檢查:沒有高血壓、糖尿病或高血脂。最近哥哥突然又發生急性心肌梗塞接受緊急心導管治療救回來。這些親人狀況令他非常焦慮，在安排例行健康檢查時，問了一連串的問題:有沒有什麼檢查可以讓他及早預防類似狀況?聽說深海魚油可以預防心血管疾病，真的嗎?聽說降血脂藥也可以預防心血管疾病，但又聽說吃降血脂藥會增加糖尿病的風險及造成腎臟病，真的嗎?那平常多吃些通血管的藥有沒有幫忙????

取自北榮實證醫學中心何主任案例

# 情境分析

四十五歲男性，事業有成，父親過去因急性心肌梗塞猝死，因此一直注重養生不抽菸。定期接受健康檢查：沒有高血壓、糖尿病或高血脂。最近哥哥突然又發生急性心肌梗塞接受緊急心導管治療救回來。這些親人狀況令他非常焦慮，在安排例行健康檢查時，問了一連串的問題：有沒有什麼檢查可以讓他及早預防類似狀況？聽說深海魚油可以預防心血管疾病，真的嗎？聽說降血脂藥也可以預防心血管疾病，但又聽說吃降血脂藥會增加糖尿病的風險及造成腎臟病，真的嗎？那平常多吃些通血管的藥有沒有幫忙????

取自北榮實證醫學中心何主任案例

# 情境分析、形成問題

## 形成問題:

- 四十五歲男性，急性心肌梗塞家族史(+)，不抽菸、沒有高血壓、糖尿病或高血脂、糖尿病或高血脂。焦慮(A型個性) [高/中/低心血管疾病風險族群?]
- [什麼]檢查可以及早預防類似狀況？篩檢或確診？
- 深海魚油可預防心血管疾病? fish oil或特別成分
- 降血脂藥可預防心血管疾病，但會增加糖尿病及造成腎臟病? statin, niacin or fibrate; Therapy vs harm
- 通血管的藥有沒有幫忙? aspirin, 銀杏(Ginkgo), plavix

取自北榮實證醫學中心何主任案例

# P.I.C.O.

P	45歲男性，急性心肌梗塞家族史(+)，A型個性[中度心血管疾病風險族群]			
Type of Q	Diagnostic	Therapy	Interventions	
I	MDCT	深海魚油	Statin	Aspirin
C	ETT	-/ healthy life style	-/ healthy life style	-/ healthy life style
O	Survey for CAD (high sensitivity)	Decrease risk of CVD	Decrease risk of CVD	Decrease risk of CVD

# 鍵入關鍵字檢索

Search Search manager Medical terms (MeSH)

Save search View searches Search help

All Text fish oi

(Word variations have been added)

- fish oil
- fish oil concentrate
- fish oil concentrates
- fish-oil concentrate

+ Clear all

若選擇建議選單中關鍵詞  
將在詞語前後加上雙引號，  
以進行詞語精確查找

Send to search manager Run search

Search Search manager Medical terms (MeSH)

Save search View searches Search help

All Text "fish oil"

"fish oil"

# 刪除空白欄位

— All Text ▼ cvd

— AND ▼ Title Abstract Keyword ▼

Error: this line cannot be blank

空白的檢索欄位亦被納入檢索  
故會查無檢索結果，  
應刪除空白欄位後再進行查找



# 儲存至 Search Manager

— Title Abstract Keyword ▼ cvd

— AND ▼ All Text ▼ "fish oil"

(Word variations have been searched)

+ [Search limits](#) [Send to search manager](#) [Run search](#)

[Clear all](#)

**Filter your results**

**Date** ⓘ

**Publication date**

The last 3 months ..... 2

The last 6 months ..... 2

The last 9 months ..... 2

The last year ..... 2

The last 2 years ..... 2

**Custom Range:**

📅 dd/mm/yyyy to 📅 dd/mm/yyyy

---

**Cochrane Reviews** 4 | **Cochrane Protocols** 0 | **Trials** 51 | **Editorials** 0 | **Special collections** 0 | **Clinical Answers** 0 | **More** ▼

**4 Cochrane Reviews matching on 'cvd in Title Abstract Keyword AND "fish oil" in All Text - (Word variations have been searched)'**

**Cochrane Database of Systematic Reviews**  
Issue 8 of 12, August 2018

**Select all (4)**    [Export selected citation\(s\)](#)    [Show all previews](#)

Order by **Relevancy** ▼    Results per page **25** ▼

1  **Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease**  
Asmaa S Abdelhamid, Tracey J Brown, Julii S Brainard, Priti Biswas, Gabrielle C Thorpe, Helen J Moore, Katherine HO Deane, Fai K AlAbdulghafoor, Carolyn D Summerbell, Helen V Worthington, Fujian Song, Lee Hooper  
[Show Preview](#) ▼    [Intervention](#)    [Review](#)    18 July 2018    [New search](#)    [Conclusions changed](#)

# Search Manager 內檢索

Search Search manager Medical terms (MeSH)

Save this search View saved searches Search help

Print

-	+	#1	(cvd):ti,ab,kw AND ("fish oil")	S	▼	▼	51
-	+	#2	("omega 3"):ti,ab,kw				
-	+	#3	#1 and #2				
-	+	#4	Manually type a search term here or click on the S (Search Wizard) or MeSH button to compose one	S	▼	MeSH	▼

欲取消編輯 記得 X 關閉

可將檢索編號與布林邏輯組合成新檢索策略

可選擇新檢索式為一般或MeSH檢索 並點按 ▼ 限縮檢索結果

欲更新檢索式需點按 Add to search line

Highlight orphan lines

Clear all

exerc  
exercise  
exercise based  
exercise bone  
exercise challenge test  
exercise induced

Add to search line

# Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Cochrane Systematic Review - Intervention | Version published: 30 November 2018 [see what's new](#) score 24[View article information](#)Asmaa S Abdelhamid | Tracey J Brown | Julii S Brainard | Priti Biswas | Gabrielle C Thorpe | Helen J Moore  
| Katherine HO Deane | Fai K AlAbdulghafoor | Carolyn D Summerbell | Helen V Worthington | Fujian Song |  Lee Hooper[View authors' declarations of interest](#)

## Abstract

### Background

Researchers have suggested that omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) benefit cardiovascular health. Guidelines recommend increasing omega-3-rich foods, and sometimes supplementation, but recent trials have not confirmed this.

### Objectives

To assess effects of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular (CVD) events, adiposity and lipids.

### Search methods

We searched CENTRAL, MEDLINE and Embase to April 2017, plus ClinicalTrials.gov and World Health Organization International Clinical Trials Registry to September 2016, with no language restrictions. We handsearched systematic review references and bibliographies and contacted authors.

### Selection criteria

We included randomised controlled trials (RCTs) that lasted at least 12 months and compared supplementation and/or advice to increase LCn3 or ALA intake versus usual or lower intake.

**下載PDF全文及引用** View PDF ▾ Cite this Review Request Permissions Comment on Review

Read comments on this Review(2)

 Print Share Email

### Abstract

Plain language summary

Authors' conclusions

Summary of findings

Background

**切換閱讀全文段落**

Discussion

Appendices

Information

Authors

History

Keywords

References

Characteristics of studies








Data and analyses

 Figures and tables Download statistical data Related content


## Appendices

### Appendix 1. Medline (Ovid) search strategy run in 2002 for the previous version of this review.

- 1 exp Fish Oils/
- 2 exp Linseed Oil/
- 3 linolenic acids/ or exp alpha-linolenic acid/
- 4 exp Fatty Acids, Omega-3/
- 5 (fish adj5 (diet\$ or nutrit\$ or oil\$ or supplement\$)).tw.
- 6 (oil\$ adj3 (cod\$ or marin\$ or rapeseed\$ or canola\$)).tw.
- 7 (omega-3 or omega3).tw.
- 8 (eicosapentaen\$ or icosapentaen\$).tw.
- 9 docosahexaen\$.tw.
- 10 (Linolen\$ or alpha-linolen\$ or alphalinolen\$).tw.
- 11 (maxepa\$ or omacor\$).tw.
- 12 (trout or kipper\$ or salmon or mackerel\$ or tuna or tunafish or sardine\$ or pilchard\$ or herring\$).tw.
- 13 flax\$.tw.
- 14 rapeseed\$.tw.
- 15 canola\$.tw.
- 16 alphalinolen\$.tw.
- 17 perilla\$.tw.
- 18 linolen\$.tw.

 View PDF ▾		
 Cite this Review		
 Request Permissions		
 Comment on Review Read comments on this Review(2)		
 Print	 Share	 Email
<b>Abstract</b>		
Plain language summary		
Authors' conclusions		
Summary of findings		
Background		
Objectives		
Methods		
Results		
Discussion		
<b>Appendices</b>		
Information		
Authors		
History		
Keywords		

## Information

DOI: [10.1002/14651858.CD003177.pub4](https://doi.org/10.1002/14651858.CD003177.pub4) 

Database: Cochrane Database of Systematic Reviews

Version published: 30 November 2018 [see what's new](#)

Type: Intervention

Stage: Review

Cochrane Editorial Group: Cochrane Heart Group

Copyright: Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## Article metrics

### Altmetric:



 Tweeted by 33






[See more details](#)


### Cited by:


*Cited 1 times via Crossref Cited-by Linking*


- 1 [Željko Reiner, Ulrich Laufs, Francesco Cosentino, Ulf Landmesser. European Heart Journal, The year in cardiology 2018: prevention, 2019, 4, 336](#)  
[Crossref](#)

[Collapse](#) 

-  [View PDF](#) 
-  [Cite this Review](#)
-  [Request Permissions](#)
-  [Comment on Review](#)  
[Read comments on this Review\(2\)](#)

  
Print

  
Share

  
Email

**Abstract**




- [Plain language summary](#)
- [Authors' conclusions](#)
- [Summary of findings](#)
- [Background](#)
- [Objectives](#)
- [Methods](#)
- [Results](#)
- [Discussion](#)

[Appendices](#)

- [Information](#)
- [Authors](#)
- [History](#)
- [Keywords](#)

[References](#)

- [Characteristics of studies](#)
- [Data and analyses](#)

-  [Figures and tables](#)
-  [Download statistical data](#)
-  [Related content](#)


## Version history


Title	Stage	Authors	Version	Publication Date
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease	Review	Asmaa S Abdelhamid, Tracey J Brown, Julii S Brainard, Priti Biswas, Gabrielle C Thorpe, Helen J Moore, Katherine HO Deane, Fai K AlAbdulghafoor, Carolyn D Summerbell, Helen V Worthington, Fujian Song, Lee Hooper	<a href="https://doi.org/10.1002/14651858.CD003177.pub4">https://doi.org/10.1002/14651858.CD003177.pub4</a>	30 November 2018
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease	Review	Asmaa S Abdelhamid, Tracey J Brown, Julii S Brainard, Priti Biswas, Gabrielle C Thorpe, Helen J Moore, Katherine HO Deane, Fai K AlAbdulghafoor, Carolyn D Summerbell, Helen V Worthington, Fujian Song, Lee Hooper	<a href="https://doi.org/10.1002/14651858.CD003177.pub3">https://doi.org/10.1002/14651858.CD003177.pub3</a>	18 July 2018
Omega 3 fatty acids for prevention and treatment of cardiovascular disease	Review	Lee Hooper, Roger A Harrison, Carolyn D Summerbell, Helen Moore, Helen V Worthington, Andrew Ness, Nigel Capps, George Davey Smith, Rudolph Riemersma, Shah Ebrahim	<a href="https://doi.org/10.1002/14651858.CD003177.pub2">https://doi.org/10.1002/14651858.CD003177.pub2</a>	18 October 2004
Omega-3 fatty acids for prevention of cardiovascular disease	Protocol	Lee L Hooper, Rachel L Thompson, Roger Harrison, Carolyn D Summerbell, Julian PT Higgins, Andy Ness, Nigel E Capps, George G Davey Smith, Rudolph A Riemersma, Shah BJ Ebrahim	<a href="https://doi.org/10.1002/14651858.CD003177">https://doi.org/10.1002/14651858.CD003177</a>	23 July 2001


## Differences between protocol and review


Differences between the previous version of this review (2004) and this update (2018):


- **Authors** altered. The Acknowledgments recognise authors of the previous version who chose not to participate in this update.
- **Background** updated.
- **Objectives: primary objective** altered from 'Do dietary or supplemental omega-3 fatty acids alter total mortality,


 [View PDF](#) ▾


 [Cite this Review](#)

 [Request Permissions](#)

 [Comment on Review](#)  
Read comments on this Review(2)

 [Print](#)

 [Share](#)

 [Email](#)

---

**Abstract**

**Plain language summary**

**Authors' conclusions**

**Summary of findings**

Background

Objectives

Methods

Results

Discussion

---

**Appendices**

---

Information

Authors

**History**

Keywords


---


References


Characteristics of studies

Data and analyses

---

 [Figures and tables](#)

 [Download statistical data](#)

 [Related content](#)

## References to studies included in this review

Jump to: [excluded studies](#) | [ongoing studies](#) | [additional references](#) | [other published versions](#)

### ADCS 2010 {published data only}

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* 2010;304(17):1903-11.

[CENTRAL](#) | [Link to article](#)

### AFFORD 2013 {published data only}

Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, et al. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. *Journal of the American College of Cardiology* 2014;64(14):1441-8.

[CENTRAL](#) | [Link to article](#) | [PubMed](#) | [CAS](#) | [Web of Science® Times Cited: 23](#)

Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A, et al. Multicentre trial of fish oil for the reduction of atrial fibrillation recurrence, inflammation and oxidative stress: the atrial fibrillation fish oil research study. *Canadian Journal of Cardiology* 2013;1:S383.

[Link to article](#)

### Ahn 2016 {published data only}

Ahn J, Park SK, Park TS, Kim JH, Yun E, Kim SP, et al. Effect of n-3 polyunsaturated fatty acids on regression of coronary atherosclerosis in statin treated patients undergoing percutaneous coronary intervention. *Korean Circulation Journal* 2016;46(4):481-9. [PUBMED: 27482256]

[CENTRAL](#) | [Link to article](#)

### AlphaOmega - ALA 2010 {published and unpublished data}

Brouwer IA, Geleijnse JM, Klaasen VM, Smit LA, Giltay EJ, Goede J, et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial. *PLOS ONE* 2013;8(12):e81519.

[Link to article](#)

Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D. Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. *European Heart Journal* 2012;33(13):1582-8.

[CENTRAL](#) | [Link to article](#) | [PubMed](#) | [CAS](#) | [Web of Science® Times Cited: 10](#)

-  [View PDF](#) ▾
-  [Cite this Review](#)
-  [Request Permissions](#)
-  [Comment on Review](#)
- [Read comments on this Review\(2\)](#)



Print



Share



Email

#### Abstract

[Plain language summary](#)

[Authors' conclusions](#)

[Summary of findings](#)

[Background](#)

[Objectives](#)

[Methods](#)

[Results](#)

[Discussion](#)

#### Appendices

#### Information

[Authors](#)

[History](#)

[Keywords](#)

#### References

[Characteristics of studies](#)

[Data and analyses](#)

 [Figures and tables](#)

 [Download statistical data](#)

 [Related content](#)

### Characteristics of included studies [ordered by study ID]

Jump to: [excluded studies](#) | [ongoing studies](#)

#### ADCS 2010

Methods	<p>Alzheimer's Disease Cooperative Study (ADCS)</p> <p>RCT, parallel, (n-3 DHA vs n-6 LA), 18 months</p> <p>Summary risk of bias: low</p>
Participants	<p>Individuals with mild to moderate Alzheimer's disease</p> <p>N: 238 intervention, 164 control</p> <p>Level of risk for CVD: low</p> <p>Men: 52.9% intervention, 40.2% control</p> <p>Mean age in years (SD): 76 (9.3) intervention, 76 (7.8) control</p> <p>Age range: unclear</p> <p>Smokers: 24.4% intervention, 21.9% control</p> <p>Hypertension: not reported</p> <p>Medications taken by at least 50% of those in the control group: cholinesterase inhibitor, memantine</p> <p>Medications taken by 20%-49% of those in the control group: none</p> <p>Medications taken by some, but less than 20% of the control group: none</p> <p>Location: USA</p> <p>Ethnicity: not reported</p>

-  [View PDF](#) ▾
-  [Cite this Review](#)
-  [Request Permissions](#)
-  [Comment on Review](#)
- [Read comments on this Review\(2\)](#)



Print



Share



Email

- Abstract**
- Plain language summary**
- Authors' conclusions**
- Summary of findings**
- Background
- Objectives
- Methods
- Results
- Discussion

#### Appendices

- Information
- Authors
- History
- Keywords

#### References

#### Characteristics of studies

#### Data and analyses

 [Figures and tables](#)

 [Download statistical data](#)



**Comparison 1.** High vs low LCn3 omega-3 fats (primary outcomes)

[Open in table viewer](#)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All-cause mortality (overall) - LCn3 <a href="#">Show forest plot</a> ▼	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
2 All-cause mortality - LCn3 - sensitivity analysis (SA) fixed-effect <a href="#">Show forest plot</a> ▼	39	90244	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.93, 1.01]
3 All-cause mortality - LCn3 - SA by summary risk of bias <a href="#">Show forest plot</a> ▼	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
3.1 Low risk of bias	15	33146	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.94, 1.08]
3.2 Moderate/high risk of bias	24	59507	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.86, 1.03]
4 All-cause mortality - LCn3 - SA by compliance and study size <a href="#">Show forest plot</a> ▼	38		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 SA - low risk of compliance bias	18	15654	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.86, 1.14]
4.2 SA - 100+ randomised	35	92397	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
5 All-cause mortality - LCn3 - subgroup by dose <a href="#">Show forest plot</a> ▼	39	92653	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.93, 1.03]
5.1 LCn3 ≤150 mg/d	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 LCn3 > 150 ≤ 250 mg/d	1	407	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.27, 2.18]

-  [View PDF](#) ▼
-  [Cite this Review](#)
-  [Request Permissions](#)
-  [Comment on Review](#)
- [Read comments on this Review\(2\)](#)

-  [Print](#)
-  [Share](#)
-  [Email](#)




- Abstract**
- Plain language summary**
- Authors' conclusions**
- Summary of findings**
- Background
- Objectives
- Methods
- Results
- Discussion

Appendices

- Information
- Authors
- History
- Keywords

- References
- Characteristics of studies

**Data and analyses**

-  [Figures and tables](#)
-  [Download statistical data](#)
-  [Related content](#)

Figures Tables

Summary of findings for the main comparison. High versus low LCn3 for preventing cardiovascular disease and mortality (primary outcomes)

Summary of findings 2. High versus low ALA omega-3 fats for preventing cardiovascular disease (primary outcomes)

Summary of findings 3. High versus low omega-3 fats for modification of CVD risk factors (adiposity and lipids): key outcomes

Table 1. Risk of bias assessment methods in greater detail

Table 2. Meta-regression results for cardiovascular mortalitya

Table 3. Meta-regression results for cardiovascular eventsa

Table 4. Meta-regression results for CHD deathsa

Table 5. Metaregression results for CHD eventsa

Table 6. Metaregression results for strokea

Figures and Tables - *Omega-3 fatty acids for the primary and secondary prevention of cardiovascular di...* ✕

[Hide table list](#)

**High versus low LCn3 for preventing cardiovascular disease and mortality (primary outcomes)**

**Patient or population:** adults with or without existing CVD

**Setting:** participants were living at home for most or all of the duration of their trials. Most studies were carried out in high-income economies (World Bank 2018), but four trials were carried out in upper-middle income countries (Argentina, Iran, Turkey and China). No studies took place in low- or low-middle income countries.

**Intervention:** higher intake of long-chain omega-3 fats

**Comparison:** lower intake of long-chain omega-3 fats

The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been: oily fish or fish oils as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or concentrated fish or algal oils, were also accepted.

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with lower LCn3	Risk with higher LCn3				
<b>All-cause mortality – deaths</b> Assessed with: number of participants dying of any cause, whether reported as an outcome or a reason for dropout  Duration: range 12 to 72 months	90 per 1,000	88 per 1,000 (83 to 92)	RR 0.98 (0.93 to 1.03)	92,653 (39 RCTs)	⊕⊕⊕⊕ High <sup>a</sup>	Meta-analysis and indications of bias suggest risk reduction of less than 2%. Long-chain omega-3 fat intake makes

Summary of findings for the main comparison. High versus low LCn3 for preventing cardiovascular disease and mortality (primary outcomes)

[Navigate to table in Review](#)

 [Figures and tables](#) [Download statistical data](#) [Related content](#)

## Download statistical data ✕

The data available are protected by copyright and may only be used in accordance with the [Terms and Conditions](#). [↗](#)

Downloaded data can only be viewed using [Review Manager software](#). [↗](#)

Please note that:

- data are only available for Cochrane Reviews that contain one or more forest plots; and
- data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.

I agree to these terms and conditions

 [Download data](#)

## Related content

Jump to: [Related reviews and protocols](#) | [Cochrane Clinical Answers](#) | [Topics](#)

## Related reviews and protocols

### [Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease](#)

Asmaa S Abdelhamid, Nicole Martin, Charlene Bridges, Julii S Brainard, Xia Wang, Tracey J Brown, Sarah Hanson, Oluseyi F Jimoh, Sarah M Ajabnoor, Katherine HO Deane, Fujian Song, Lee Hooper | **27 November 2018**

### [Fibrates for secondary prevention of cardiovascular disease and stroke](#)

Deren Wang, Bian Liu, Wendan Tao, Zilong Hao, Ming Liu | **25 October 2015**

[View more](#) ▾

## Cochrane Clinical Answers

### [How do high and low concentrations of long-chain fatty acids \(LCn3\) compare for primary and secondary prevention of cardiovascular disease?](#)

Jane Burch, Sera Tort | **19 December 2018**

### [How do high and low concentrations of alpha linolenic acid \(ALA\) compare for primary and secondary prevention of cardiovascular disease?](#)

Jane Burch, Sera Tort | **19 December 2018**





## Topics

### Complementary & alternative medicine

↳ [Heart & circulation](#)

↳ [Heart disease prevention](#)

[Heart & circulation](#)

-  [View PDF](#) ▾
-  [Cite this Review](#)
-  [Request Permission](#)
-  [Comment on Review](#)  
[Read comments on this review](#)

 [Print](#)

 [Share](#)

### [Abstract](#)

[Plain language summary](#)

[Authors' conclusions](#)

[Summary of findings](#)

[Background](#)

[Objectives](#)

[Methods](#)

[Results](#)

[Discussion](#)

[Appendices](#)

[Information](#)

[Authors](#)

[History](#)

[Keywords](#)

[References](#)

[Characteristics of studies](#)

[Data and analyses](#)

 [Figures and tables](#)

 [Download statistics](#)

 [Related content](#)

# Clinical Answers

# Clinical Answers

- Cochrane Clinical Answers(CCAs) 針對Cochrane 系統性文獻回顧中嚴謹的研究結果，**提供使用者一個易讀、易懂且切入重點的臨床決策參考**。
- 每個 CCAs 涵蓋**臨床問題**、**解答摘要**，以及從Cochrane reviews 可深入探究的相關性證據。實證結合情境敘述、數據與圖表，以可讀性高的介面呈現，讓使用者更容易獲得所需要的臨床解答。
- 主要使用族群為健康照護醫護專業人員與健康照護決策者。
- CCAs 以 Cochrane 高質量系統性文獻回顧為基礎，專注於以「**病人安全**」為中心，CCAs 提供醫護人員權威且專業的實證臨床問題解答。

# 瀏覽 Clinical Answers

[Cochrane Reviews](#) ▾
 [Trials](#) ▾
 **[Clinical Answers](#)** ▾
 [About](#) ▾
 [Help](#) ▾

[Browse Clinical Answers](#)  
[About Clinical Answers](#)

Cochrane Reviews 7756	Cochrane Protocols 2445	Trials 1297153	Editorials 120	Special collections 24	Clinical Answers 1764	More ▾
--------------------------	----------------------------	-------------------	-------------------	---------------------------	--------------------------	-----------

**Filter your results**

Date ⓘ

Publication date

The last 3 months..... 132

The last 6 months..... 218

The last 9 months..... 307

The last year ..... 441

The last 2 years ..... 884

Custom Range:

to

Topics ⓘ

**1764 Clinical Answers matching on '\* in All Text'**

**Cochrane Clinical Answers**


**Select all (1764)**    Export selected citation(s)

Order by  ▾      Results per page  ▾

- How does verapamil compare with adenosine for people with supraventricular tachycardia?**  
 Jane Burch, Benilde Cosmi  
 30 March 2018
- What are the benefits and harms of nutritional support for hospitalized adults at nutritional risk?**  
 Jane Burch, Sascha Köpke  
 28 February 2018
- What are the effects of niacin for primary and secondary prevention of cardiovascular events?**

# 檢索Clinical Answers

檢索完後，在結果頁面直接點選Clinical Answers即可。



The screenshot shows the Cochrane Clinical Answers search results page. At the top, there are navigation tabs for different content types: Cochrane Reviews (111), Cochrane Protocols (15), Trials (16426), Editorials (2), Special collections (0), and Clinical Answers (15). The 'Clinical Answers' tab is highlighted with an orange border. Below the tabs, the search results are displayed for the query 'lung cancer in Title Abstract Keyword - (Word variations have been searched)'. The results are sorted by Relevancy and show 15 results per page. The first three results are:

- What are the benefits and harms of screening for lung cancer?**  
Jane Burch, John C Ruckdeschel  
25 July 2016
- What are the effects of gefitinib in people with advanced non-small cell lung cancer?**  
Sera Tort, Serife Eti  
3 September 2018
- In healthy people, can combinations of vitamins/selenium help to prevent lung cancer?**  
Jane Burch, Kwun M Fong  
3 August 2016



## Question:

# What are the benefits and harms of screening for lung cancer?

Jane Burch, John C Ruckdeschel  
| 25 July 2016

## Clinical Answer:

**Available randomized controlled trial data does not support screening for lung cancer with chest X-ray with or without sputum cytology. Screening with low dose CT may reduce lung-cancer mortality in smokers, but effects in other populations need to be further assessed.**

Moderate to high-quality evidence shows that more intense screening (with chest X-ray +/- sputum cytology) had similar effects than less intense screening on lung cancer mortality; however, when longer follow-up data was added, lung cancer mortality was higher with more intense screening; this may be a consequence of overtreatment. Conversely, low to moderate-quality evidence shows higher lung cancer 5-year survival with more intense screening. High-quality evidence shows no benefit of annual chest X ray compared with no regular screening on lung cancer mortality at 6 or 13 years' follow-up but when annual-low dose CT was compared with annual chest X-ray in smokers or former smokers, lung cancer mortality was lower. Benefits for CT screening in people with a history of smoking would have been even higher if it had been compared with the community standard (no screening) rather than with X-ray. Harms were poorly reported and mostly associated with subsequent invasive investigations and death post-surgery, but harms directly related to screening were not reported.

## Comparisons

1. 4 to 12 monthly screening versus less frequent screening (chest X-ray +/- sputum cytology)	Expand All »
2. Annual chest X-ray screening versus no regular screening	Expand All »
3. Annual low dose computed tomography (CT) screening versus annual chest X-ray	Expand All »

[Cite this Answer](#)  
[Request Permissions](#)

 Print

 Share

 Email

Answer

Comparisons

Additional Information

 Figures

 Related content

**1. 4 to 12 monthly screening versus less frequent screening (chest X-ray +/- sputum cytology)**
[Collapse All](#)
**▼ OUTCOME 1.1 Lung cancer mortality (duration unclear – seems to be 3 years)**
**Narrative result**

Studies evaluating more frequent chest x-ray screening versus less frequent screening, and annual chest X-ray plus 4-monthly cytology versus annual X-ray alone, were reported separately. There were no statistically significant difference between groups for either analysis. Click below for full details.[1]

**Reference**

Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D. Screening for lung cancer. *Cochrane Database of Systematic Reviews* 2013, Issue 6. Art. No.: CD001991. DOI: 10.1002/14651858.CD001991.pub3. [Review search date: May 2012]

› **Subgroup analysis 1.1.1 Lung cancer mortality - [subgroup: More frequent chest X-ray screening versus less frequent screening]**

› **Subgroup analysis 1.1.2 Lung cancer mortality - [subgroup: Annual chest X-ray plus 4-monthly cytology versus annual X-ray alone]**

**▼ OUTCOME 1.2 Lung cancer mortality (including longer follow-up data (seems to be up to 6 years))**
**Narrative result**

Studies reporting more frequent chest X-ray screening versus less frequent screening found higher mortality with more intense screening. In contrast, studies comparing annual chest X-ray plus 4-monthly cytology versus annual X-ray alone found no statistically significant difference between groups. Click below for full details.[4]

**Reference**

Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D. Screening for lung cancer. *Cochrane Database of Systematic Reviews* 2013, Issue 6. Art. No.: CD001991. DOI: 10.1002/14651858.CD001991.pub3. [Review search date: May 2012]

› **Subgroup analysis 1.2.1 Lung cancer mortality (longer follow-up) - [subgroup: More frequent chest X-ray screening versus less frequent screening]**

## 翻譯志工招募

「讓全世界看到你!!!」考科藍摘要中文翻譯志工招募計畫

一、計畫簡介：CDSR (Cochrane Database of Systematic Reviews) 為考科藍圖書館 (the Cochrane Library) 的子資料庫之一，收錄大量系統性文獻回顧相關的研究論文及摘要，2016年Cochrane review之科學引文索引 (Science Citation Index, SCI) 的影響係數 (Impact Factor) 為6.124。考科藍臺灣研究中心(由臺北醫學大學實證醫學研究中心升格，以下簡稱本中心) 持續進行CDSR摘要繁體中文的翻譯工作，並發布至考科藍圖書館資料庫，供全球華語健康照護者查詢及閱讀，以促進實證醫學知識之傳遞及交流。為增加考科藍圖書館中繁體中文資料的數量及品質，及拓展臺灣能見度，本中心持續招募「考科藍摘要中文翻譯志工」，除了讓國際看見臺灣在實證醫學領域的用心與努力外，也將在翻譯文稿末尾留下譯者大名以表彰譯者之貢獻，讓全世界看到你！

二、翻譯流程：加入翻譯志工後，我們會依據志工的專業領域挑選**1~2**篇英文摘要，連同「翻譯原則」一起Email給志工。志工完成中文翻譯後，在文末註明服務單位及大名，於**1**個月內回覆本中心，由本中心審稿後將翻譯稿件上傳至Cochrane Library網頁，再進行下一次的翻譯。

三、計畫聯絡方式：Email：cochranetaiwan@tmu.edu.tw；電話：02-27361661#7323

四、註冊申請志工：於Cochrane Join us網頁(<http://join.cochrane.org/>)進行申請註冊程序，詳細步驟如附檔。

備註：本翻譯計畫為志願參加(無提供翻譯費)，本中心保有翻譯文章修改及上傳至Cochrane Library之最終權利。

### 活動

- 醫學人工智慧 「從如果/然後到擬人學習」

### 相關網站

- Cochrane Taiwan
- East Asian Cochrane Alliance
- International Society of Evidence-Based Healthcare, Taiwan
- The Cochrane Collaboration
- The Cochrane Library
- Unbound Medicine
- 台灣實證醫學學會
- 考科藍中文版
- 考科藍台灣 Cochrane Taiwan 粉絲專頁
- 行政院衛生福利部

# MeSH search

※請善用此檢索方式

# 檢索問題

## 用詞不一致

- 同樣指癌症，有人使用「cancer」，有人使用「tumor」，需把相同概念的各式同義詞及狹義詞完整蒐集，查找文獻才不會遺漏。

## 需過濾不相關文獻

- 輸入的關鍵字可能只與文章某處有關聯，但並非文章重點，需花大量時間過濾「出現這個字但實際上並不相關」的文章。

# MeSH Search

醫學主題詞表 ( Medical Subject Headings ; 簡稱MeSH )

- 美國國家醫學圖書館 ( National Library of Medicine ) 出版
- 分析生物醫學方面之期刊文獻等資源的主題內容之控制語彙表
- NLM出版之MEDLINE/PubMed資料庫主題檢索的索引典。



# 使用MeSH的好處

- 可以協助找出**精確**符合主題的資料
  - 無須煩惱因縮寫、別名而**遺漏**相關文獻
  - 使用**同義詞**也可準確查詢出相關文獻資料
- 使用MeSH Tree
  - 可以**依需求擴展**或**縮小**查詢範圍
  - 了解各醫學標題的橫向與縱向關聯
  - **MeSH Tree**可顯示標題間分類的層級關係。最上層顯示者，表示該標題詞所代表的主題意涵較廣（generic），而愈下層顯示者，則表示所代表的主題意涵愈為特異（specific）。

1 Neoplasms

2 Select subheadings / qualifiers

3 Look up Clear

想查詢治療cancer的藥物資料，就選擇drug therapy

- abnormalities - AB
- administration & dosage - AD
- adverse effects - AE
- agonists - AG
- analogs & derivatives - AA
- analysis - AN
- anatomy & histology - AH
- antagonists & inhibitors - AI

View saved searches ? Search help

Look up Clear

### Definition

**Neoplasms** - New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

### Thesaurus Matches

#### Exact Term Match

#### Neoplasms

Synonyms: Neoplasm; Tumors; Neoplasias; Tumor; Neoplasia; Benign Neoplasm; Benign Neoplasms; Neoplasm, Benign; Neoplasms, Benign; Malignancies; Neoplasm, Malignant; Malignant Neoplasm; Neoplasms, Malignant; Malignancy; Malignant Neoplasms; Cancers; Cancer

#### Phrase Matches

Abdominal Neoplasms 77

### MeSH Trees

MeSH term - **Neoplasms**

- Explode all trees
- Single MeSH term (unexploded)
- Explode selected trees

Select

#### Tree number 1

- Neoplasms [+15]
- Cysts [+26]
- Hamartoma [+3]
- Neoplasms by Histologic Type [+14]
- Neoplasms by Site [+17]
- Neoplasms, Experimental [+10]
- Neoplasms, Hormone-Dependent

### Search Results

There are **22564** results for your search on

- MeSH descriptor: Neoplasms
- Explode all trees
- With qualifier(s) therapy

4 顯示各子庫中所查詢到的筆數

Trials	22334
Cochrane Reviews	230

Save search

5

View results

點選View Results



結果頁面中首先呈現Cochrane Review中收錄的236筆關於治療“癌症”的可用藥物資料(橘色框框)，可做為醫療人員使用的參考

1

### **Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia**

Mo'iad Alazzam, John Tidy, Raymond Osborne, Robert Coleman, Barry W Hancock, Theresa A Lawrie

[Show Preview](#) [Intervention](#) [Review](#) [13 January 2016](#) [New search](#) [Free access](#)

2

### **Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer**

Elvira C van Dalen, Martine F Raphaël, Huib N Caron, Leontien CM Kremer

[Show Preview](#) [Intervention](#) [Review](#) [4 September 2014](#) [New search](#) [Conclusions changed](#) [Free access](#)

3

### **Systemic treatments for metastatic cutaneous melanoma**

Tom Crosby, Reg Fish, Bernadette Coles, Malcolm Mason

[Show Preview](#) [Intervention](#) [Review](#) [7 February 2018](#) [Withdrawn](#) [Free access](#)

4

### **Adjuvant chemotherapy for small intestine adenocarcinoma**

Nimit Singhal, Deepti Singhal

[Show Preview](#) [Intervention](#) [Review](#) [18 July 2007](#)

5

### **Danazol for uterine fibroids**

Lin -qiu Ke, Kun Yang, Chun-Mei Li, Jing Li

[Show Preview](#) [Intervention](#) [Review](#) [8 July 2009](#)

# SEARCH MANAGER

[Search](#)[Search manager](#)[Medical terms \(MeSH\)](#)[Save search](#)[View searches](#)[? Search help](#)

1

(Word variations have been searched)

2

[Search limits](#)[Send to search manager](#)[Run search](#)

## Advanced Search

Please note that the Advanced Search is optimised for English search terms. Certain features, such as search operators and MeSH terms, are only available in English.

[Search](#)
[Search manager](#)
[Medical terms \(MeSH\)](#)

[Save this search](#)
[View saved searches](#)
[Search help](#)

+/-	#1	(CVD):ti,ab,kw AND (fish oil)	S	61	
+/-	#2	MeSH descriptor: [Neoplasms] explode all trees	MeSH	67072	
+/-	#3	#1 AND #2		3	
+/-	#4	Manually type a search term here or click on the S (Search Wizard) or MeSH button to compose one	S	MeSH	N/A

Clear all

4

Save search

Enter search name

Enter comments

儲存此檢索策略

3

[Save this search](#)
[View saved searches](#)
[Search help](#)

Print

Saved searches



Order by date - Newest first

1 0326

Last saved: 26/03/2018 12:00:20

將此檢索策略重新載入Search Manager，並可重新檢索

設定當有符合檢索策略的新Review文章發表時，自動寄送通知至帳號信箱

e-mail alert Load Append Share Export Delete

2 1106

Last saved: 07/11/2017 13:56:05

e-mail alert Load Append Share Export Delete

將此檢索策略載入到現有檢索策略後方，以便進一步組合編輯

3 1106demo

Last saved: 06/11/2017 14:37:54

e-mail alert Load Append Share Export Delete

以複製連結或Email傳送分享此檢索策略

4 1106

Share saved search



To share this search, copy the URL or send via email.

Cancel

Copy URL

Send link via email

以純文字檔(.txt)匯出此檢索策略

Cancel

# 在Search中儲存檢索結果

## Advanced Search

Please note that the Advanced Search is optimised for English search terms. Certain features, such as search operators and MeSH terms, are only available in English.

Search Search manager Medical terms (MeSH)

Save search View searches Search help

All Text CVD

(Word variations have been searched)

+

Search limits Send to search manager Run search

Clear all

### Saved searches

You have 2 saved searches

1 common cold in Title Abstract Keyword (Word variations have been searched) Last saved: 17/08/2018 17:27	<input type="checkbox"/> e-mail alert	Load	Export	Delete
2 "acupressure" in Title Abstract Keyword (Word variations have been searched) Last saved: 17/08/2018 16:19	<input type="checkbox"/> e-mail alert	Load	Export	Delete

Cancel

View searches 可查看所有儲存歷史

Please note that the Advanced Search is optimised for English search terms. Certain features, such as search operators and MeSH terms, are only available in English.

[Search](#)
[Search manager](#)
[Medical terms \(MeSH\)](#)

### Definition

**Neoplasms** - New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

### Thesaurus Matches

#### Exact Term Match

Neoplasms

Synonyms: Neoplasm, Benign; Benign Neoplasm; Benign Neoplasms; Neoplasms, Benign; Malignant Neoplasms; Neoplasms, Malignant; Malignancies; Cancer; Neoplasm, Malignant; Malignant Neoplasm; Cancers; Malignancy; Tumors; Neoplasias; Tumor; Neoplasm; Neoplasia

#### Phrase Matches

Cancer Care Facilities

Synonyms: Hospital, Cancer; Cancer Hospitals; Hospitals, Cancer; Cancer Hospital; Facility, Cancer Care; Facilities, Cancer Care; Cancer Care Facility

American Cancer Society

### MeSH Trees

MeSH term - **Neoplasms**

- Explode all trees
- Single MeSH term (unexploded)
- Explode selected trees

#### Tree number 1

**Neoplasms [+15]**  
**Cysts [+26]**  
**Hamartoma [+3]**  
**Neoplasms by Histologic Type [+14]**  
**Neoplasms by Site [+17]**  
**Neoplasms, Experimental [+10]**  
**Neoplasms, Hormone-Dependent**  
**Neoplasms, Multiple Primary [+3]**  
**Neoplasms, Post-Traumatic**  
**Neoplasms, Radiation-Induced [+1]**  
**Neoplasms, Second Primary**  
**Neoplastic Processes [+8]**

### Search Results

There are **22564** results for your search on

- MeSH descriptor: Neoplasms
- Explode all trees
- With qualifier(s) drug therapy

Trials	22334
Cochrane Reviews	230

## Advanced Search

Please note that the Advanced Search is optimised for English search terms. Certain features, such as search operators and MeSH terms, are only available in English.

Search Search manager Medical terms (MeSH)

Save this search View saved searches Search help

Print

-	+	#1	(CVD):ti,ab,kw AND (fish oil)	S	▼	▼	61	
-	+	#2	MeSH descriptor: [Neoplasms] explode all trees	MeSH	▼		67073	
-	+	#3	#1 AND #2			▼	3	
-	+	#4	Manually type a search term here or click on the S (Search Wizard) or MeSH button to compose one	S	▼	MeSH	▼	N/A

✕ Clear all  Highlight orphan lines

Save this search View saved searches Search help

Print



Saved searches

Order by date - Newest first ▼

1 0813  
Last saved: 13/08/2018 09:42:51

e-mail alert ⬆ Load + Append ↶ Share ⬇ Export ✖ Delete

2 08101  
111  
Last saved: 10/08/2018 17:07:00

3 0326  
Last saved: 26/03/2018 12:00:20

4 1106

Saved MeSH searches

Order by date - Newest first ▼

1 MeSH descriptor: [Anesthesia, General] explode all trees  
Last saved: 13/06/2017 15:07

e-mail alert ⬆ Load ⬇ Export ✖ Delete

在MeSH及Search Manager當中，可另外勾選e-mail alert進行檢索結果追蹤，當儲存的檢索策略有新資料時即會自動寄送通知信到e-mail提醒

# 書目匯出

- Cochrane Reviews 76
- Cochrane Protocols 1
- Trials 1649
- Editorials 1
- Special collections 0
- Clinical Answers 2
- More

76 Cochrane Reviews matching on 'common cold in Title Abstract Keyword - (Word variations have been searched)'

Cochrane Database of Systematic Reviews

Issue 8 of 12, August 2018

Select all (76) **Export selected citation(s)** Show all previews

Order by Relevancy

Results per page 25



Antihistamines for the common cold

An IM D... Sutter, M... Lemiengre, M... Campbell

Show full record

Export selected citation(s)

1 citation(s) selected for download

Save citation to:  Mendeley  RefWorks



Select the format you require from the list below

Plain text **RIS (EndNote)** | RIS (Reference Manager) | RIS (ProCite) | BibTeX

Preview of format

```
ID: CD001267
AU: De Sutter AIM
AU: Lemiengre M
AU: Campbell H
TI: Antihistamines for the common cold
SO: Cochrane Database of Systematic Reviews
YR: 2009
NO: 4
PB: John Wiley & Sons, Ltd
```



Include abstract **Download**



Garlic for the common cold

## Filter your results

Date

Publication date

The last 3 months ..... 2

The last 6 months ..... 4

The last 9 months ..... 5

The last year ..... 8

The last 2 years ..... 8

Custom Range:

to

**Apply** **Clear**

Status

New search ..... 26

Conclusions changed ..... 6

Language

Español ..... 45

Show 12 more

Type

Intervention ..... 76

EndNote X9 - [My EndNote Library]

File Edit References Groups Tools Window Help

Medicine Quick Search Hide Search Panel

Search Options Search Whole Group Match Case Match Words

Author Contains

And Year Contains

Author	Year	Title	Rating	Journal/Secondary Title	Last Updated	Reference Type	Code
de Souza...	2012	Interventions for managing...		Cochrane Database o...	2018/8/10	Journal Article	
De Sutter...	2009	Antihistamines for the com...		Cochrane Database o...	2018/8/10	Journal Article	
De Sutter...	2015	Antihistamines for the com...		Cochrane Database o...	2018/8/10	Journal Article	
De Sutter...	2012	Oral antihistamine-decong...		Cochrane Database o...	2018/8/10	Journal Article	
Deckx, L.;...	2016	Nasal decongestants in mo...		Cochrane Database o...	2018/8/10	Journal Article	
East, C. E....	2012	Local cooling for relieving ...		Cochrane Database o...	2018/8/10	Journal Article	
Ennis, H.;...	2016	Calcium channel blockers f...		Cochrane Database o...	2018/8/10	Journal Article	
Fernande...	2013	Glucocorticoids for acute vi...		Cochrane Database o...	2018/8/10	Journal Article	
French S...	2006	Superficial heat or cold for ...		Cochrane Database o...	2018/8/10	Journal Article	

Reference Preview

Reference Type: Journal Article

**Rating**  
.....

**Author**  
de Souza, R. F.  
Lovato da Silva, C. H.  
Nasser, M.  
Fedorowicz, Z.  
Al-Muharraqi, M. A.

Attached PDFs

There are no PDFs attached to this reference.

# Q & A *Thank You!*

碩睿資訊有限公司

客服電話：(02)7731-5800

客戶服務信箱：[services@customer-support.com.tw](mailto:services@customer-support.com.tw)